181 related articles for article (PubMed ID: 29185289)
21. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.
Kim JT; Kim YM; Jung KY; Choi H; Lee SY; Kim HJ
Korean J Intern Med; 2024 Jan; 39(1):148-159. PubMed ID: 38145616
[TBL] [Abstract][Full Text] [Related]
23. [Vitamin D deficiency in postmenopausal women receiving osteoporosis therapy].
Kraljević I; Kastelan D; Gorsić I; Solak M; Giljević Z; Kasović M; Sertić J; Korsić M
Lijec Vjesn; 2007; 129(8-9):304. PubMed ID: 18198632
[No Abstract] [Full Text] [Related]
24. A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study.
Kim KJ; Hong N; Lee S; Kim M; Rhee Y
Calcif Tissue Int; 2020 Dec; 107(6):567-575. PubMed ID: 32920682
[TBL] [Abstract][Full Text] [Related]
25. Denosumab-related hypocalcaemia in chronic kidney disease.
Yong CH
Aust J Gen Pract; 2018 Aug; 47(8):538-539. PubMed ID: 30114884
[No Abstract] [Full Text] [Related]
26. Denosumab (prolia) for postmenopausal osteoporosis.
Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
[No Abstract] [Full Text] [Related]
27. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
Daga N; Joseph F
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
[TBL] [Abstract][Full Text] [Related]
28. Severe hypocalcemia following denosumab injection in patient with chronic kidney disease.
Monge Rafael P; Arias M; Fernández-Fresnedo G
Nefrologia; 2016; 36(4):446-8. PubMed ID: 27012438
[No Abstract] [Full Text] [Related]
29. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
30. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
[TBL] [Abstract][Full Text] [Related]
31. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
Watthanasuntorn K; Abid H; Gnanajothy R
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567243
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
Diédhiou D; Cuny T; Sarr A; Norou Diop S; Klein M; Weryha G
Ann Endocrinol (Paris); 2015 Dec; 76(6):650-7. PubMed ID: 26639186
[TBL] [Abstract][Full Text] [Related]
33. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
34. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
35. How Long to Treat with Denosumab.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2015 Dec; 13(6):415-20. PubMed ID: 26474564
[TBL] [Abstract][Full Text] [Related]
36. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
McCormick BB; Davis J; Burns KD
Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
[TBL] [Abstract][Full Text] [Related]
37. Hypocalcaemia after denosumab in older people following fracture.
Chen J; Smerdely P
Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
[TBL] [Abstract][Full Text] [Related]
38. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
39. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
40. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
